Riskpilot← Back to searchSign inGet full accessMandrillo Pharma AB
ABActiveOrg 5569314916Tåghusa 142Activities of advertising agencies · NACE 7311Est. 20130 employees
Revenue 2025
SEK 373
-99% vs 2024
EBITDA margin
-5038.1%
+91% vs 2024
Equity ratio
94.3%
Financial strength
Net profit 2025
SEK -18K
+91% vs 2024
| Revenue | SEK 373 | -99% |
| EBITDA | SEK -19K | +91% |
| Net profit | SEK -18K | +91% |
| Total assets | SEK 176K | -15% |
| Equity | SEK 166K | -10% |
| Employees | 0 | — |
Legal name
Mandrillo Pharma AB
Org number
5569314916
Legal form
Aktiebolag
NACE code
7311 · Activities of advertising agencies
Founded
13 maj 2013
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-06-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Bolaget skall bedriva konsultverksamhet inom reklam, marknadsföring, event och försäljning och handel med egenvårds- och friskvårdsprodukter för människor och djur och därmed förenlig verksamhet.
Address
Tåghusa 142
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 666 | 191 | 63 | 53 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −57 | −73 | −26 | −211 | −19 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | −57 | −73 | −26 | −211 | −19 |
| Net financials | — | −0 | 0 | 0 | 0 |
| Profit before tax | −57 | −73 | −26 | −211 | −18 |
| Tax | −1 | — | — | — | — |
| Net profit | −58 | −73 | −26 | −211 | −18 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 652 | 533 | 417 | 207 | 176 |
| Equity | 494 | 421 | 395 | 185 | 166 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 157 | 112 | 21 | 22 | 10 |
| Total debt | 157 | 112 | 21 | 22 | 10 |
EBITDA margin
-5038.1%
This company
15.8%
Market median
-31987% vs market
20212025
Equity ratio
94.3%
This company
38.2%
Market median
+147% vs market
20212025
Return on equity
-11.1%
This company
18.4%
Market median
-160% vs market
20212025
Net profit margin
-4956.0%
This company
8.1%
Market median
-61285% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
0.06×
This company
0.62×
Market median
+90% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-07-01 – 2025-06-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-07-01 – 2024-06-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-07-01 – 2023-06-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-07-01 – 2022-06-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-07-01 – 2021-06-30
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
PG Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Chairman | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Mandrillo Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Pål Göran Wederbrand | Chief Executive Officer | 0 companies |
| Gertrud Anita Wederbrand | Board of Directors | 0 companies |
| Kaj Jörgen Månsson | Chairman | 0 companies |